Correlation Between Aquestive Therapeutics and Accretion Acquisition

Can any of the company-specific risk be diversified away by investing in both Aquestive Therapeutics and Accretion Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aquestive Therapeutics and Accretion Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aquestive Therapeutics and Accretion Acquisition Corp, you can compare the effects of market volatilities on Aquestive Therapeutics and Accretion Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aquestive Therapeutics with a short position of Accretion Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aquestive Therapeutics and Accretion Acquisition.

Diversification Opportunities for Aquestive Therapeutics and Accretion Acquisition

-0.67

Correlation Coefficient

Aquestive Therapeutics  Accretion Acquisition

Excellent diversification

The 3 months correlation between Aquestive and Accretion is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Aquestive Therapeutics and Accretion Acquisition Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Accretion Acquisition and Aquestive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aquestive Therapeutics are associated (or correlated) with Accretion Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Accretion Acquisition has no effect on the direction of Aquestive Therapeutics i.e., Aquestive Therapeutics and Accretion Acquisition go up and down completely randomly.

Pair Corralation between Aquestive Therapeutics and Accretion Acquisition

Given the investment horizon of 90 days Aquestive Therapeutics is expected to generate 21.01 times more return on investment than Accretion Acquisition. However, Aquestive Therapeutics is 21.01 times more volatile than Accretion Acquisition Corp. It trades about 0.08 of its potential returns per unit of risk. Accretion Acquisition Corp is currently generating about 0.15 per unit of risk. If you would invest  99.00  in Aquestive Therapeutics on October 3, 2024 and sell it today you would earn a total of  257.00  from holding Aquestive Therapeutics or generate 259.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	26.26%
Values	Daily Returns

Aquestive Therapeutics  vs.  Accretion Acquisition Corp

Aquestive Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aquestive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Accretion Acquisition

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Accretion Acquisition Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Accretion Acquisition is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Aquestive Therapeutics and Accretion Acquisition

The main advantage of trading using opposite Aquestive Therapeutics and Accretion Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aquestive Therapeutics position performs unexpectedly, Accretion Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accretion Acquisition will offset losses from the drop in Accretion Acquisition's long position.

The idea behind Aquestive Therapeutics and Accretion Acquisition Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.